EUVIMEDEUVIMED entdecken
Studienprotokoll

Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial

Manouk den Toom, Laura Blanken, Inge Horn, Selene Veerman, Joris J B van der Vlugt-Molenaar, Mariken B de Koning, Jan Bogers, John Enterman, Martin de Jonge, Daniela Cianci, Gerardus W J Frederix, Hans J de Haas und 10 weitere

Pharmacopsychiatry · 01.11.2024 · 57 (06) · 290-295

DOI: 10.1055/a-2364-4357 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Pharmacopsychiatry, erschienen am 01.11.2024. Verfasst von Manouk den Toom und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Amsterdam UMC, The Netherlands. Hauptthemen laut MEDLINE: Antipsychotic Agents, Aripiprazole, Clozapine, Electroconvulsive Therapy. Die Arbeit nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, guidance on the most effective treatment for patients with clozapine-resistant schizophrenia-spectrum disorders (SSD) is lacking. While augmentation strategies to clozapine with aripiprazole and electroconvulsive therapy (ECT) have been demonstrated to be effective in patients with clozapine-resistant schizophrenia spectrum disorders (CRS), head-to-head comparisons between these addition strategies are unavailable. We therefore aim to examine the feasibility of a larger randomized, single-blind trial comparing the effectiveness, cost-effectiveness, and safety of aripiprazole addition vs. ECT addition in CRS.

Methods

In this multi-center, randomized, single-blind feasibility study, the feasibility of recruiting 20 participants with CRS who will be randomized to either aripiprazole or bilateral ECT addition will be assessed. The main endpoint is the number of patients willing to be randomized. The number of screened individuals and reasons to decline participation will be recorded. Effects will be estimated for the benefit of the foreseen larger trial. To that end, differences between both arms in symptom severity will be assessed using blinded video assessments. In addition, tolerability (e. g., cognitive functioning), safety, quality of life, recovery, and all-cause discontinuation will be compared. The follow-up period is 16 weeks, after which non-responders will be given the option to switch to the other treatment.

Discussion

Strengths of this feasibility trial include maintaining blinding with video assessment, a possibility to switch groups in case of non-response, and a broad set of outcome measures. Identification of factors contributing to non-participation and drop-out will generate valuable information on trial feasibility and may enhance recruitment strategies in a follow-up RCT.

Trial registration

The study has been approved by the Medical Research Ethics Committee of the Amsterdam University Medical Center, location AMC, and was registered on 1 May 2022 in the EU Clinical Trials Register (EudraCT) under the trial name ‘EMECLO’ (2021–006333–19).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsAripiprazoleClozapineElectroconvulsive TherapyFeasibility StudiesAdultFemaleHumansMaleMiddle AgedYoung AdultCombined Modality TherapyMulticenter Studies as TopicSchizophreniaSchizophrenia, Treatment-ResistantSingle-Blind MethodTreatment Outcome

Substanzen

Antipsychotic AgentsAripiprazoleClozapine

Autor:innen und Institutionen

  • Department of Psychiatry, Amsterdam UMC, The Netherlands.
  • Department of Psychiatry, Dijklander Ziekenhuis, Hoorn, Netherlands.
  • MS centrum, Amsterdam UMC, The Netherlands.
  • Mental Health Service Noord Holland Noord, The Netherlands.
  • Antes - Parnassia Group, Rotterdam, The Netherlands.
  • Arkin Mental Health Care, Amsterdam, The Netherlands.

Zitieren

APA

den Toom, M., Blanken, L., Horn, I., Veerman, S., van der Vlugt-Molenaar, J. J. B., de Koning, M. B., Bogers, J., Enterman, J., de Jonge, M., Cianci, D., Frederix, G. W. J., de Haas, H. J., Storosum, B. W., Veereschild, M., Javadzadeh, M., Schulte, P. F. J., Cohen, D., van Os, J., Cahn, W., …, & Luykx, J. J. (2024). Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial. Pharmacopsychiatry, 57(06), 290-295. https://doi.org/10.1055/a-2364-4357

Vancouver

den Toom M, Blanken L, Horn I, Veerman S, van der Vlugt-Molenaar JJB, de Koning MB, et al. Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial. Pharmacopsychiatry. 2024;57(06):290-295. doi:10.1055/a-2364-4357

BibTeX
@article{denToom2024,
  author = {den Toom, Manouk and Blanken, Laura and Horn, Inge and Veerman, Selene and van der Vlugt-Molenaar, Joris J B and de Koning, Mariken B and Bogers, Jan and Enterman, John and de Jonge, Martin and Cianci, Daniela and Frederix, Gerardus W J and de Haas, Hans J and Storosum, Bram W and Veereschild, Mike and Javadzadeh, Martin and Schulte, Peter F J and Cohen, Dan and van Os, Jim and Cahn, Wiepke and de Haan, Lieuwe and Zantvoord, Jasper B and Luykx, Jurjen J},
  title = {Electroconvulsive Therapy Versus Aripiprazole Addition to Clozapine in Patients with Clozapine-Resistant Symptoms (EMECLO): A Protocol of a Single-Blind, Multicenter, Randomized-Controlled Feasibility Trial},
  journal = {Pharmacopsychiatry},
  year = {2024},
  volume = {57},
  number = {06},
  pages = {290--295},
  doi = {10.1055/a-2364-4357}
}
Kostenlos starten →